Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 5.58% | $35.94M | €435.69B | 66.23% | 76 Outperform | |
| Roche Holding AG | 4.50% | $29.01M | CHF287.79B | 43.00% | 73 Outperform | |
| Novartis AG | 4.23% | $27.21M | CHF225.91B | 20.41% | 80 Outperform | |
| Advantest | 3.40% | $21.87M | ¥18.64T | 195.60% | 75 Outperform | |
| Rolls-Royce Holdings | 2.84% | $18.28M | £102.67B | 121.16% | 71 Outperform | |
| Allianz | 2.69% | $17.29M | €146.71B | 24.43% | 67 Neutral | |
| SAFRAN SA | 2.67% | $17.18M | €123.73B | 25.14% | 67 Neutral | |
| Unilever | 2.55% | $16.45M | £112.92B | -0.65% | 72 Outperform | |
| GlaxoSmithKline | 2.24% | $14.45M | £83.92B | 40.07% | 77 Outperform | |
| ABB Ltd | 2.23% | $14.35M | kr1.41T | 37.47% | 78 Outperform |